{"id":4557,"date":"2017-07-20T15:14:30","date_gmt":"2017-07-20T15:14:30","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=4557"},"modified":"2023-09-25T14:03:18","modified_gmt":"2023-09-25T14:03:18","slug":"fin-du-recrutement-patients-pour-lessai-clinique-odyssee-de-maat-pharma","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/fin-du-recrutement-patients-pour-lessai-clinique-odyssee-de-maat-pharma\/","title":{"rendered":"Fin du recrutement patients pour l&rsquo;essai clinique Odyss\u00e9e de MaaT Pharma"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h3 style=\"text-align: center;\">Fin du recrutement patients pour l \u2019essai clinique Odyss\u00e9e de MaaT Pharma<\/h3>\n<p>&nbsp;<\/p>\n<p>30 mois seulement apr\u00e8s sa cr\u00e9ation, MaaT Pharma atteint son objectif de patients trait\u00e9s dans sa premi\u00e8re \u00e9tude clinique Odyss\u00e9e. La biotech teste l\u2019efficacit\u00e9 de son candidat m\u00e9dicament MaaT001.3 utilisant le Transfert de Microbiote F\u00e9cal autologue chez des individus atteints de Leuc\u00e9mie Aigu\u00eb My\u00e9loblastique. La fin du recrutement positionne MaaT Pharma parmi les soci\u00e9t\u00e9s les plus matures de l\u2019industrie prometteuse du Microbiome.<\/p>\n<p>Lyon (France), le 20 juillet 2017 \u2013 MaaT Pharma, MicrobioTech1 europ\u00e9enne qui d\u00e9veloppe des traitements innovants bas\u00e9s sur le microbiote intestinal en onco-h\u00e9matologie et en infectiologie, annonce la finalisation du recrutement des patients trait\u00e9s dans le cadre de l\u2019\u00e9tude Odyss\u00e9e avec MaaT 001.3, m\u00e9dicament issu de sa recherche interne.<\/p>\n<p>Cette \u00e9tude clinique est un essai multicentrique men\u00e9e en France chez des patients atteints de Leuc\u00e9mie Aigue My\u00e9loblastique (LAM). Ces patients souffrent d\u2019une dysbiose iatrog\u00e9nique, induite par les traitements de chimioth\u00e9rapie et \/ ou antibiotiques. Le candidat m\u00e9dicament MaaT001.3 leur est alors administr\u00e9 post\u00e9rieurement aux traitements contre la leuc\u00e9mie. La reconstitution du microbiote intestinal est \u00e9valu\u00e9e 10 jours apr\u00e8s le Transfert de Microbiote F\u00e9cal (TMF) autologue et celle-ci constitue le crit\u00e8re principal de l\u2019essai clinique Odyss\u00e9e.<\/p>\n<p><strong>Un recrutement finalis\u00e9 pour des r\u00e9sultats pr\u00e9liminaires prometteurs<\/strong><\/p>\n<p>Le recrutement est d\u00e9sormais complet, 25 patients ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s depuis septembre 2016. Cette rapidit\u00e9 de recrutement t\u00e9moigne de l\u2019int\u00e9r\u00eat de la communaut\u00e9 m\u00e9dicale. Les analyses pr\u00e9liminaires indiquent une restauration structurelle et fonctionnelle de la symbiose h\u00f4te-microbiote. Par ailleurs, le Data Safety Monitoring Board a valid\u00e9 la poursuite de l\u2019\u00e9tude sur la base des donn\u00e9es de s\u00e9curit\u00e9 disponibles. Odyss\u00e9e servira de base pour le lancement d\u2019un programme clinique phase II<br \/>\nambitieux, d\u00e9j\u00e0 en pr\u00e9paration.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<blockquote><p>\u00ab Cette \u00e9tude constitue \u00e0 ce jour, la plus importante \u00e9tude europ\u00e9enne sur une cohorte de patients atteints de Leuc\u00e9mie Aigue My\u00e9loblastique trait\u00e9s avec un produit de TMF fabriqu\u00e9 selon les standards pharmaceutiques, \u00bb<\/p><\/blockquote>\n<p>commente Herv\u00e9 Affagard, CEO de MaaT Pharma.<\/p>\n<blockquote><p>\u00ab Nous pensons que des r\u00e9sultats positifs issus de notre \u00e9tude pourraient ouvrir la voie au d\u00e9veloppement de plusieurs m\u00e9dicaments bas\u00e9s sur le TMF dans le traitement des diff\u00e9rentes indications en onco-h\u00e9matologie \u00bb.<\/p><\/blockquote>\n<p><em>Les r\u00e9sultats d\u00e9finitifs sont attendus au dernier trimestre 2017. MaaT Pharma soumettra \u00e9galement un abstract pour le congr\u00e8s annuel de l\u2019American Society of Hematology qui se tiendra \u00e0 Atlanta en d\u00e9cembre 2017.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Le microbiome, un investissement d\u2019avenir<\/strong><\/p>\n<p>Les r\u00e9centes avanc\u00e9es dans la recherche sur le microbiome sont prometteuses et ouvrent de nouvelles voies th\u00e9rapeutiques pour les m\u00e9decins et patients dans les maladies infectieuses, le cancer, les maladies immuno-d\u00e9ficientes, l\u2019ob\u00e9sit\u00e9, l\u2019autisme, etc. En parall\u00e8le de l\u2019augmentation des publications scientifiques, les investissements dans les biotechs du microbiome se sont multipli\u00e9s ; \u00e0 l\u2019image des \u00c9tats-Unis qui ont fait le choix de lancer en 2016 sous la pr\u00e9sidence de Barack Obama \u00ab The National Microbiome Initiative \u00bb dot\u00e9 d\u2019un fond de plus de 120 millions de dollars destin\u00e9 \u00e0 la recherche. La France quant \u00e0 elle, \u00e0 travers le PIA (Programme d\u2019Investissements d\u2019Avenir), soutient \u00e9galement les biotechs du secteur comme MaaT Pharma, premi\u00e8re MicrobioTech \u00e0 r\u00e9aliser du Transfert de Microbiote F\u00e9cal (TMF) pour les patients atteints de leuc\u00e9mie aigu\u00eb.<\/p>\n<p>Initialement pionni\u00e8re dans le Transfert de Microbiote F\u00e9cal autologue, MaaT Pharma d\u00e9veloppe aujourd\u2019hui des m\u00e9dicaments utilisant des microbiotes autologues et allog\u00e9niques. Port\u00e9e par sa croissance exponentielle, MaaT Pharma s\u2019est associ\u00e9 \u00e0 Biocodex dans l\u2019objectif de d\u00e9velopper une forme orale de son m\u00e9dicament. Un pas suppl\u00e9mentaire vers l\u2019industrialisation de la TMF pour la biotech qui a mis au point le premier dispositif m\u00e9dical marqu\u00e9 CE pour la collecte et dilution des selles.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_highlighted_text color_type=\u00a0\u00bbregular\u00a0\u00bb highlight_color=\u00a0\u00bb#f2c836&Prime; style=\u00a0\u00bbhalf_text\u00a0\u00bb]<em><strong>\u00c0 propos de MaaT Pharma<\/strong><\/em><\/p>\n<p>MaaT Pharma (Microbiota as a Therapy) est une start-up en biotechnologie cr\u00e9\u00e9e en 2014. MaaT Pharma d\u00e9veloppe des solutions th\u00e9rapeutiques, bas\u00e9es sur le transfert de microbiote intestinal, pour traiter les maladies graves li\u00e9es \u00e0 la dysbiose intestinale (d\u00e9s\u00e9quilibres du microbiote intestinal). MaaT Pharma d\u00e9veloppe des solutions autologues (donneur et receveur identiques) et allog\u00e9niques (depuis un donneur) de transfert de microbiote intestinal, chez des patients trait\u00e9s pour des Leuc\u00e9mie My\u00e9loblastique Aigu\u00eb ou encore des infections ost\u00e9o-articulaires, destin\u00e9es \u00e0 maximiser les chances de r\u00e9ussite des traitements de ces pathologies. L\u2019approche de MaaT Pharma, r\u00e9volutionnaire et rapide, participe consid\u00e9rablement aux \u00e9volutions des th\u00e9rapies individuelles.<br \/>\nFort des 16 millions d\u2019euros de financement re\u00e7us, la soci\u00e9t\u00e9 multiplie les partenariats avec des \u00e9tablissements de renom, comme l\u2019INRA, l\u2019Institut Gustave Roussy, Bioaster, etc. Dans les mois \u00e0 venir, MaaT Pharma poursuivra ses programmes de d\u00e9veloppement, et pr\u00e9pare sa prochaine lev\u00e9e de fonds avec l\u2019objectif de lancer une forme orale de m\u00e9dicament destin\u00e9e \u00e0 la TMF, d\u2019ici 2018, avec une mise sur le march\u00e9 en 2022.<br \/>\nMaaT Pharma est soutenu dans son d\u00e9veloppement par ses investisseurs experts du domaine du Microbiome et des d\u00e9veloppements technologiques : Seventure, CM-CIC Innovations, Biocodex et l\u2019INRA.<\/p>\n<p>Pour plus d\u2019informations : www.maatpharma.com \/ @MaaT_Pharma[\/nectar_highlighted_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb color_override=\u00a0\u00bb#5bc0cc\u00a0\u00bb icon_family=\u00a0\u00bbiconsmind\u00a0\u00bb text=\u00a0\u00bbSee more\u00a0\u00bb margin_top=\u00a0\u00bb50&Prime; url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/09\/FR_FINAL_CP-Fin-de-recrutement-v0.2.pdf\u00a0\u00bb icon_iconsmind=\u00a0\u00bbiconsmind-Mouse-Pointer\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":4438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[53],"class_list":{"0":"post-4557","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-53"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fin du recrutement patients pour l&#039;essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fin du recrutement patients pour l&#039;essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/?p=3868\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-20T15:14:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T14:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"766\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"Fin du recrutement patients pour l&rsquo;essai clinique Odyss\u00e9e de MaaT Pharma\",\"datePublished\":\"2017-07-20T15:14:30+00:00\",\"dateModified\":\"2023-09-25T14:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868\"},\"wordCount\":1527,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868\",\"name\":\"Fin du recrutement patients pour l'essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"datePublished\":\"2017-07-20T15:14:30+00:00\",\"dateModified\":\"2023-09-25T14:03:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/?p=3868\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\",\"width\":1441,\"height\":766},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/?p=3868#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fin du recrutement patients pour l&rsquo;essai clinique Odyss\u00e9e de MaaT Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fin du recrutement patients pour l'essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Fin du recrutement patients pour l'essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/?p=3868","og_site_name":"MaaT Pharma","article_published_time":"2017-07-20T15:14:30+00:00","article_modified_time":"2023-09-25T14:03:18+00:00","og_image":[{"width":1441,"height":766,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"Fin du recrutement patients pour l&rsquo;essai clinique Odyss\u00e9e de MaaT Pharma","datePublished":"2017-07-20T15:14:30+00:00","dateModified":"2023-09-25T14:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868"},"wordCount":1527,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868","url":"https:\/\/maat.swebwp.oci.eu\/?p=3868","name":"Fin du recrutement patients pour l'essai clinique Odyss\u00e9e de MaaT Pharma - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","datePublished":"2017-07-20T15:14:30+00:00","dateModified":"2023-09-25T14:03:18+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/?p=3868"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","width":1441,"height":766},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/?p=3868#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"Fin du recrutement patients pour l&rsquo;essai clinique Odyss\u00e9e de MaaT Pharma"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=4557"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4557\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/4438"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=4557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=4557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=4557"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=4557"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=4557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}